Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
19 mai 2022 17h00 HE
|
Radius Health Inc.; The Menarini Group
EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in...
Radius Health, Inc. First Quarter 2022 Results
05 mai 2022 07h30 HE
|
Radius Health Inc.
Q1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021° Q1 results: in-line with previously guided 1H 2022 company target of $97 million° Reiterating FY 2022 TYMLOS Net Revenue...
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
25 avr. 2022 08h30 HE
|
Radius Health Inc.
BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday,...
Radius Provides Agenda for Today’s R&D Webcast
05 avr. 2022 08h00 HE
|
Radius Health Inc.
Focus: RAD011, an investigational synthetic cannabidiol oral solutionWebcast details: 10:00am to 12:00pm for current or prospective investors and sell side analystsObjectives: asset overview, science,...
Radius Health Announces Leadership Appointments
16 mars 2022 08h30 HE
|
Radius Health Inc.
BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective...
Radius Health Provides Business Update on Bone Health
08 mars 2022 08h30 HE
|
Radius Health Inc.
Exclusive extension of research discovery collaboration with Mass General Hospital (MGH)Focus of the program: development of novel oral SIK inhibitors for musculoskeletal diseasesExtension of activity...
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
07 mars 2022 08h30 HE
|
Radius Health Inc.
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a...
Radius to Host Neuroscience R&D Webcast April 5, 2022
03 mars 2022 16h05 HE
|
Radius Health Inc.
Focus: RAD011, our investigational synthetic cannabidiol oral solutionBroad market interest in the underlying science, data, and clinical translation of the assetGoal: provide foundational review of...
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis
01 mars 2022 08h00 HE
|
Radius Health Inc.
Filed sNDA with the FDA ahead of schedule on Friday, February 25, 2022Filing based on the positive ATOM study data previously announced on October 18, 2021There is a 10-month FDA review BOSTON, March...
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
24 févr. 2022 07h30 HE
|
Radius Health Inc.
Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208...